๐Ÿ’‰

Tesamorelin

Tesamorelin is a synthetic version of human growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to the pituitary telling it to release growth hormone. Unlike
๐Ÿ’‰
Sermorelin
(which is a shorter 1-29 fragment) or
๐Ÿ’‰
CJC-1295
(a modified 1-29 with albumin binding), tesamorelin is the full 44 amino acid GHRH molecule with a single N-terminal modification that protects it from rapid breakdown. The defining feature is what it actually does in humans: it preferentially shrinks visceral fat, the deep abdominal fat that sits around your organs and drives metabolic disease, by roughly 15-20% over 6 months.
Most people interested in tesamorelin are middle-aged adults with stubborn belly fat that won't respond to diet and training, or people with fatty liver. The visceral-fat-specific effect is what separates it from every other GHRH peptide. It's also the only GHRH analogue with full FDA approval (as Egrifta, for HIV-associated lipodystrophy) and the largest peer-reviewed evidence base of the class. The trade-off is daily injections, real metabolic side effects (insulin resistance is the most important one), and a price tag that varies enormously depending on source.

Deep-dive

GH is released in pulses from the anterior pituitary under two opposing controls, GHRH (the gas pedal) and somatostatin (the brake), with ghrelin acting as a third input that amplifies the GHRH signal. Tesamorelin is the full GHRH (1-44) sequence with a trans-3-hexenoyl group attached to the N-terminal tyrosine. That single modification blocks cleavage by DPP-IV, the enzyme that destroys native GHRH within minutes, and extends the functional half-life enough to be clinically useful from a once-daily subcutaneous injection.
Pharmacokinetics. Plasma half-life is roughly 26-38 minutes, longer than
๐Ÿ’‰
Sermorelin
(around 11-12 minutes) but much shorter than
๐Ÿ’‰
CJC-1295
with DAC (5-8 days). Bioavailability is low (under 4% subcutaneously) which is why the standard clinical dose is 2 mg, much higher than other GHRH peptides. The pulse pattern is preserved, tesamorelin produces a single extended GH pulse per dose rather than collapsing pulsatility into a flat elevation, which is the cleanest argument for it over the DAC version. Pituitary somatostatin feedback still cycles between doses.
Why visceral fat specifically. GH is strongly lipolytic and visceral fat has a higher density of GH receptors and is more responsive to GH-driven lipolysis than subcutaneous fat. People with low endogenous GH (HIV-associated lipodystrophy, general obesity, aging) accumulate visceral fat preferentially, and restoring GH pulsatility preferentially strips it back off. This is the mechanism explanation behind the central trial findings.
Phase 3 trials in HIV-associated lipodystrophy. The Falutz 2007 NEJM trial randomised 412 HIV patients with excess abdominal fat to 2 mg subcutaneous tesamorelin or placebo daily for 26 weeks. Visceral adipose tissue dropped 15.2% on tesamorelin versus a 5% increase on placebo, triglycerides dropped, the cholesterol-to-HDL ratio improved, and adiponectin rose. Insulin sensitivity didn't worsen meaningfully at 26 weeks. A second confirmatory Phase 3 trial replicated the effect. The pooled analysis (Falutz 2010 JCEM) across 816 patients out to 52 weeks confirmed sustained VAT reduction in responders, no liver-related adverse events, and similar adverse event rates between tesamorelin and placebo. Around 60-70% of treated patients meet the predefined responder criterion of at least 8% VAT reduction. Discontinuing tesamorelin causes the visceral fat to come back, this is a maintenance therapy, not a cure.
Liver fat. Tesamorelin is the first compound shown to reduce hepatic steatosis in HIV-associated fatty liver. The Stanley 2014 JAMA trial gave 50 HIV patients with abdominal fat accumulation tesamorelin or placebo for 6 months and saw a net 16.6% reduction in visceral fat and a significant reduction in liver fat fraction. The Stanley 2019 Lancet HIV trial ran 12 months in 61 HIV patients with NAFLD (liver fat โ‰ฅ5%) and found 35% of the tesamorelin group dropped below the NAFLD threshold versus 4% of placebo, and tesamorelin prevented progression of liver fibrosis. The hepatic transcriptomic data from this trial (Fourman 2020 JCI Insight) shows tesamorelin upregulates oxidative phosphorylation pathways and downregulates inflammatory and fibrotic pathways in the liver. This is the strongest mechanistic evidence in the class for a drug effect on liver fat beyond simple weight loss. Non-HIV NAFLD trials are underway but data is still emerging.
Cognition. The Baker 2012 trial randomised 152 older adults (55-87 years old, 76 healthy and 61 with mild cognitive impairment) to nightly subcutaneous tesamorelin (1 mg) or placebo for 20 weeks. The treated group improved on executive function tests, with comparable benefit in healthy and MCI groups. Verbal memory improved in the MCI subgroup specifically. IGF-1 levels rose toward young-adult ranges and stayed elevated. Fasting insulin rose 35% in the MCI group but not the healthy group, the most important caveat in the trial. This builds on Vitiello's 2006 sermorelin trial and is the strongest cognitive evidence in the GHRH peptide class. A more recent 2025 trial in HIV with neurocognitive impairment showed only a trend toward cognitive improvement that wasn't statistically significant against standard of care.
Muscle and body composition beyond fat. The Adrian 2019 trial used CT to measure muscle in HIV patients on tesamorelin and found increased muscle area and reduced muscle fat infiltration after 26 weeks. The phase 3 trials also showed modest improvements in lean mass alongside the visceral fat reduction. Total body weight doesn't change much because the fat loss is regional, this isn't a weight-loss drug, it's a fat-distribution drug.
Why people pick tesamorelin over the alternatives. Three reasons. One, it's the only GHRH analogue with FDA approval and substantial Phase 3 evidence behind it, which translates to better-characterised dosing, safety, and quality control through Egrifta. Two, the visceral-fat-specific effect is documented in humans, unlike
๐Ÿ’‰
CJC-1295
, where body composition claims are extrapolated. Three, the liver-fat data is unique to tesamorelin in this class. The trade-offs are cost (Egrifta is around $3,000 per month at brand price, compounded versions are typically $150-300 per month), the daily injection schedule, and a meaningfully higher rate of glucose-handling side effects than the lower-dose stacks like
๐Ÿ’‰
CJC-1295
+
๐Ÿ’‰
Ipamorelin
.
Anecdotal pattern. Across off-label use reports, the most consistently reported effects are visible waist reduction (typically noticeable around 2-3 months, more substantial by 6 months), faster recovery from training, deeper sleep within the first 1-2 weeks, and improved skin firmness over 2-3 months. Less consistent: noticeable muscle gain (most people don't gain visible mass without also training), mood changes, libido. Common complaints: facial flushing in the first 30-60 minutes after injection (vasodilatory GHRH effect, fades after the first few doses), injection-site reactions (the most common side effect in trials, 24-37% of patients), mild water retention, hand and foot tingling at the upper dose end. People with prediabetes or borderline fasting glucose often see their numbers move in the wrong direction, this matches the trial data and is the most predictable downside.
Women. This is one of the few peptides with substantial female enrollment in trials. The phase 3 program required waist circumference >94 cm for women and >95 cm for men, with eligibility set deliberately to enroll both sexes. Women generally responded at similar rates to men on the primary VAT endpoint, though the Mangili 2015 predictors analysis found baseline metabolic syndrome, elevated triglycerides, and white race were stronger predictors of response than sex. The Baker cognition trial enrolled both sexes and found comparable cognitive benefit. Practically, women use the same 2 mg daily dose as men, and the menopausal transition is biologically a particularly relevant window because endogenous GH output drops alongside oestrogen and visceral fat distribution shifts during this period. The bone-density angle matters here too given the GH-IGF-1 axis's role in maintaining bone turnover. Skip tesamorelin in pregnancy and breastfeeding, the GH/IGF-1 axis is tightly regulated and there's no safety data.
Older adults. GH output declines roughly 14% per decade after age 30, and visceral fat accumulation accelerates with the drop. The Baker cognition trial specifically targeted adults 55-87 and the metabolic trials skewed middle-aged. This is the population the compound was studied in and where the risk-benefit picture is best understood. The long-term safety question, particularly around insulin resistance and cancer risk, is the weakest part of the picture and is covered in the side effects section.
Limitations of the evidence. The phase 3 program was conducted in HIV-associated lipodystrophy, which is a specific metabolic context. Whether the effect size in non-HIV middle-aged adults with central obesity is the same is being studied but not yet definitively answered. There are no head-to-head trials against
๐Ÿ’‰
CJC-1295
,
๐Ÿ’‰
Sermorelin
, or GLP-1 drugs for visceral fat. The fat returns once you stop, indefinite use isn't well-studied, and the longest controlled human trial ran 18 months. Cost is a real practical barrier for off-label use at brand pricing, and compounded sources vary in quality even within legitimate 503A/503B pharmacies.

Dosage:

  • Standard dose: 2 mg subcutaneous, once daily. This is the dose used in every Phase 3 trial and is what Egrifta is supplied as. Some off-label protocols start at 1 mg daily for the first 2-4 weeks to assess tolerance, then move to 2 mg. Some users run 1-1.4 mg long-term to reduce side effects, but the trial evidence is at 2 mg
  • Timing: Inject before bed on an empty stomach. Pre-bed dosing aligns with the natural nighttime GH surge during deep sleep. Avoid food (especially carbs and protein) within 2 hours of injection, elevated insulin and circulating amino acids blunt the GH pulse via pituitary feedback
  • Reconstitution: Comes as lyophilised powder (typical research vials are 5 mg or 10 mg). Reconstitute with bacteriostatic water, store refrigerated, and use within roughly 30 days. Egrifta-SV ships with prefilled sterile diluent and is stable longer. Subcutaneous injection into abdominal fat or thigh with an insulin syringe. Rotate sites
  • Cycling: Phase 3 trial protocols ran continuous daily dosing for 6-12 months. Off-label cycling protocols often run 3-6 months on, 1-2 months off, partly to recheck IGF-1 and glucose markers and partly because the visceral fat reduction plateaus and most of the benefit accrues in the first 6 months. Visceral fat re-accumulates within months of stopping, this isn't a one-and-done protocol
  • Women: Same 2 mg daily dose. Perimenopausal and postmenopausal women may notice the metabolic effects more because endogenous GH baseline is lower. No specific dose adjustment is needed based on sex in the published literature
  • Stacking: Tesamorelin is sometimes combined with
    ๐Ÿ’‰
    Ipamorelin
    for the GHRH plus ghrelin pathway synergy, similar logic to the CJC-1295 + ipamorelin stack. Most stacks pair 1-2 mg tesamorelin pre-bed with 100-200 mcg ipamorelin. Stacking with exogenous HGH is redundant and shuts down the natural pulse. Stacking with the DAC version of CJC-1295 is also redundant since both stimulate GHRH receptors
  • Sourcing: Egrifta-SV is the branded FDA-approved product, manufactured under cGMP, and the cleanest source if cost isn't a barrier (around $3,000/month brand price, often lower with patient assistance programs). Tesamorelin is also legally available through US 503A and 503B compounding pharmacies with a prescription, typically $150-300/month. Tesamorelin was not on the FDA 503A Category 2 list, unlike most peptides in this space, because it has its own approved BLA. Grey-market "research use only" vials are the cheapest but quality varies and dose accuracy is unreliable

Here's what you can expect:

The first thing most people notice, usually within the first 1-2 weeks, is deeper sleep and some facial flushing for the first 30-60 minutes after each injection. Recovery from training tends to feel faster within the first month. Visible waist reduction is gradual and typically becomes obvious between months 2 and 3, with most of the visceral fat loss accruing through month 6. The change is regional (waist circumference and abdominal CT-measured visceral fat), not total weight, the scale may barely move while the waist drops several centimetres. Skin firmness and hydration improvements come over 2-3 months alongside the body composition shift.
If you're already lean with low visceral fat, the effect will be much less dramatic, the compound preferentially strips visceral fat from people who have excess of it. Response rates in trials were around 60-70%, meaning a real subset of users don't hit the threshold response and the predictors are metabolic syndrome, elevated triglycerides, and baseline visceral fat burden. Fasting glucose and HbA1c may drift up over the first 3 months, this is the predictable metabolic cost and needs to be tracked.

Side effects & risks:

  • Injection site reactions are by far the most common side effect, mild redness, itching, occasional bruising. Around 24-37% of trial participants reported them. Rotate sites
  • Facial flushing and warmth in the first 30-60 minutes after injection. The vasodilatory effect of GHRH receptor activation. Harmless, usually fades after the first few doses
  • Arthralgia (joint aches), myalgia, and peripheral oedema are reported in 5-10% of users, the typical pattern for elevated GH/IGF-1
  • Mild water retention and tingling (paraesthesia) in hands and feet at the upper dose. Early sign of carpal tunnel-type symptoms from elevated GH/IGF-1. Reversible. Reduce dose
  • Insulin resistance and elevated fasting glucose. This is the most important metabolic concern with tesamorelin specifically, and is more pronounced than with the lower-dose peptide stacks because tesamorelin is dosed higher and produces more sustained GH output. The Baker cognition trial showed a 35% rise in fasting insulin in the MCI subgroup. The Phase 3 metabolic data showed modest glucose changes on average but a meaningful tail of patients with significant worsening. Recheck fasting glucose and HbA1c at 3 months without fail. If fasting glucose creeps above 100 mg/dL or HbA1c above 5.7%, reduce dose or stop
  • Active or recent cancer, avoid. IGF-1 is mitogenic and elevated IGF-1 is epidemiologically associated with increased risk of several cancers (colorectal, prostate, breast) over long timescales. Hard contraindication if you have a current or recent cancer diagnosis. The trial data did not show an increased cancer signal but trials were not powered or long enough to detect this
  • Diabetic retinopathy can worsen with elevated GH/IGF-1. Avoid if you have any active diabetic eye disease
  • Sleep apnoea can worsen with GH elevation due to soft tissue changes, monitor if you have it
  • Pregnancy and breastfeeding: avoid
  • Pituitary tumour or unexplained hyperprolactinaemia: avoid until worked up
  • Hypothyroidism: GH stimulation can unmask underlying low thyroid output, screen before starting
  • Discontinuation rebound. Visceral fat returns within months of stopping. Plan for either indefinite use (with ongoing metabolic monitoring) or accept that the body composition gains are not durable without other interventions (training, diet, possibly maintenance dosing)
  • Long-term safety beyond 18 months. The longest controlled human trial ran 12 months with a 6-month open-label extension. Beyond that, you're inferring safety from related GH/IGF-1 literature. The IGF-1 elevation tesamorelin produces sits in a range associated with epidemiological cancer risk increases over decades, this is a real long-term consideration
  • Cost and access. Egrifta-SV brand pricing is around $3,000/month. Compounded tesamorelin through legitimate US 503A/503B pharmacies is typically $150-300/month and is the practical option for most off-label users. Grey-market "research use only" product is unreliable in identity and dose. Tesamorelin sits outside the 2023 FDA Category 2 list because it has its own approved BLA, so the regulatory environment is more stable than for compounded sermorelin, CJC-1295, or ipamorelin
  • WADA prohibits it in competition

๐Ÿฉธ

Blood markers

IGF-1, baseline and at 6-8 weeks. The most useful single marker for whether the compound is working and at what intensity. Aim for the upper end of the age-adjusted reference range, not above it. Tesamorelin reliably produces larger IGF-1 elevations than sermorelin or low-dose stacks.
Fasting glucose and HbA1c, baseline and at 3 months without exception. This is the most important monitoring marker for tesamorelin specifically because the dose is high and the glucose effect is the most clinically meaningful side effect. If fasting glucose creeps above 100 mg/dL or HbA1c above 5.7%, reduce dose or stop.
Fasting insulin and HOMA-IR, baseline and at 3 months. More sensitive read on insulin resistance than glucose alone, particularly relevant given the Baker trial finding of a 35% insulin rise in MCI patients.
Full lipid panel, baseline and at 3 months. Tesamorelin reliably lowers triglycerides in the trial data, an upside worth tracking. Total cholesterol and LDL may shift in either direction.
ALT and AST, baseline and at 3 months. Particularly relevant if you have any history of fatty liver. The Phase 3 data showed liver enzymes improved with VAT reduction, but track them anyway.
TSH, free T4, free T3, baseline. GH can suppress TSH and shift T4 to T3 conversion. Worth knowing if you have thyroid history.
Waist circumference and ideally a CT or DEXA visceral fat measurement, baseline and at 6 months. The actual outcome the compound is dosed for. If you're spending $150-3,000/month on this, you should measure whether it's working.
For most people the practical minimum is IGF-1 + fasting glucose + HbA1c + waist circumference at baseline and at 3 months. The glucose markers are non-negotiable on this compound.

FDA-approved as Egrifta and Egrifta-SV for HIV-associated lipodystrophy. Off-label use is widespread and tesamorelin is available through US 503A/503B compounding pharmacies under prescription. Not approved for human use in most other jurisdictions outside the HIV indication.